Regulatory T cells, tumour immunity and immunotherapy.

STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer (2009) 15.45

Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol (2010) 6.04

Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest (2007) 5.05

Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell (2009) 4.56

Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Invest (2007) 4.44

Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. J Clin Invest (2010) 3.97

Metformin prevents tobacco carcinogen--induced lung tumorigenesis. Cancer Prev Res (Phila) (2010) 3.86

Tregs and rethinking cancer immunotherapy. J Clin Invest (2007) 3.77

B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med (2006) 3.75

IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol (2010) 3.43

T(H)17 cells in tumour immunity and immunotherapy. Nat Rev Immunol (2010) 3.39

Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med (2011) 3.12

Suppression of autophagy by FIP200 deletion inhibits mammary tumorigenesis. Genes Dev (2011) 3.05

Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J Pathol (2010) 3.03

Cancer immunology--analysis of host and tumor factors for personalized medicine. Nat Rev Clin Oncol (2011) 2.90

Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes. Blood (2009) 2.88

Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma. J Clin Oncol (2008) 2.77

Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J Clin Invest (2013) 2.77

Development of TLR9 agonists for cancer therapy. J Clin Invest (2007) 2.64

Immune surveillance: a balance between protumor and antitumor immunity. Curr Opin Genet Dev (2008) 2.62

Tackling the cancer stem cells - what challenges do they pose? Nat Rev Drug Discov (2014) 2.55

PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood (2009) 2.54

Helminth secretions induce de novo T cell Foxp3 expression and regulatory function through the TGF-β pathway. J Exp Med (2010) 2.54

OX40 costimulation turns off Foxp3+ Tregs. Blood (2007) 2.52

Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans. Proc Natl Acad Sci U S A (2013) 2.47

Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy. Proc Natl Acad Sci U S A (2009) 2.47

OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection. J Exp Med (2008) 2.46

Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human colorectal cancer. Cancer Immun (2007) 2.44

T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res (2012) 2.43

Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS One (2009) 2.36

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci Transl Med (2016) 2.16

Immune cell promotion of metastasis. Nat Rev Immunol (2015) 2.15

Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors. Cell (2016) 2.15

IL-17 promotes tumor development through the induction of tumor promoting microenvironments at tumor sites and myeloid-derived suppressor cells. J Immunol (2010) 2.12

Immunotherapy of cancer in 2012. CA Cancer J Clin (2012) 2.12

How tolerogenic dendritic cells induce regulatory T cells. Adv Immunol (2010) 2.11

Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells. Int J Cancer (2011) 2.05

Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma. Gastroenterology (2009) 2.04

Regulatory T cells and treatment of cancer. Curr Opin Immunol (2008) 2.01

Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. Semin Oncol (2010) 1.98

Foxp3 expression in human cancer cells. J Transl Med (2008) 1.94

CCR5-dependent homing of naturally occurring CD4+ regulatory T cells to sites of Leishmania major infection favors pathogen persistence. J Exp Med (2006) 1.88

PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. Cancer Res (2011) 1.87

Regulatory T-cell compartmentalization and trafficking. Blood (2006) 1.86

Deciphering the role of Th17 cells in human disease. Trends Immunol (2011) 1.76

Amphiregulin enhances regulatory T cell-suppressive function via the epidermal growth factor receptor. Immunity (2013) 1.75

Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Ann Oncol (2012) 1.73

Use of tumour-responsive T cells as cancer treatment. Lancet (2009) 1.73

Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma. J Clin Invest (2009) 1.73

Lymphocytes in cancer development: polarization towards pro-tumor immunity. Cytokine Growth Factor Rev (2009) 1.68

Targeting regulatory T cells in cancer. Cancer Res (2011) 1.66

2011: the immune hallmarks of cancer. Cancer Immunol Immunother (2011) 1.66

A20 is an antigen presentation attenuator, and its inhibition overcomes regulatory T cell-mediated suppression. Nat Med (2008) 1.65

OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis. J Exp Med (2009) 1.63

The composition and signaling of the IL-35 receptor are unconventional. Nat Immunol (2012) 1.63

Selective and efficient generation of functional Batf3-dependent CD103+ dendritic cells from mouse bone marrow. Blood (2014) 1.60

Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus. Mol Ther (2011) 1.60

Regulation of antitumor immune responses by the IL-12 family cytokines, IL-12, IL-23, and IL-27. Clin Dev Immunol (2010) 1.59

The impact of regulatory T cells on T-cell immunity following hematopoietic cell transplantation. Blood (2007) 1.57

Epigenetic quantification of tumor-infiltrating T-lymphocytes. Epigenetics (2011) 1.57

Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma. J Immunol (2013) 1.53

Ability of mature dendritic cells to interact with regulatory T cells is imprinted during maturation. Cancer Res (2008) 1.53

Role of Stat3 in suppressing anti-tumor immunity. Curr Opin Immunol (2008) 1.52

Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. Proc Natl Acad Sci U S A (2014) 1.52

Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo. J Immunol (2007) 1.52

Therapeutic opportunities for manipulating T(Reg) cells in autoimmunity and cancer. Nat Rev Drug Discov (2013) 1.50

Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming. Proc Natl Acad Sci U S A (2008) 1.49

Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes. Nat Biotechnol (2015) 1.47

Aryl hydrocarbon receptor ligands in cancer: friend and foe. Nat Rev Cancer (2014) 1.46

TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression. PLoS One (2012) 1.44

Costimulatory and coinhibitory receptors in anti-tumor immunity. Immunol Rev (2009) 1.44

Molecular mechanisms of treg-mediated T cell suppression. Front Immunol (2012) 1.41

Interplay between regulatory T cells and PD-1 in modulating T cell exhaustion and viral control during chronic LCMV infection. J Exp Med (2014) 1.40

Cancer inflammation and regulatory T cells. Int J Cancer (2010) 1.40

Regulatory T-cell homeostasis: steady-state maintenance and modulation during inflammation. Immunol Rev (2014) 1.38

Global Regulatory T-Cell Research from 2000 to 2015: A Bibliometric Analysis. PLoS One (2016) 1.38

Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis. PLoS One (2011) 1.38

Neuropilin 1 deficiency on CD4+Foxp3+ regulatory T cells impairs mouse melanoma growth. J Exp Med (2012) 1.38

Tumor-induced immune suppression of in vivo effector T-cell priming is mediated by the B7-H1/PD-1 axis and transforming growth factor beta. Cancer Res (2008) 1.38

Tumor-infiltrating γδ T lymphocytes predict clinical outcome in human breast cancer. J Immunol (2012) 1.38

Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia. Clin Cancer Res (2009) 1.37

Bimodal viral vectors and in vivo imaging reveal the fate of human neural stem cells in experimental glioma model. J Neurosci (2008) 1.36

Tumor-associated macrophages recruit CCR6+ regulatory T cells and promote the development of colorectal cancer via enhancing CCL20 production in mice. PLoS One (2011) 1.36

Interactions of tumor cells with dendritic cells: balancing immunity and tolerance. Cell Death Differ (2007) 1.35

Higher intratumoral infiltrated Foxp3+ Treg numbers and Foxp3+/CD8+ ratio are associated with adverse prognosis in resectable gastric cancer. J Cancer Res Clin Oncol (2010) 1.34

Selective recruitment of regulatory T cell through CCR6-CCL20 in hepatocellular carcinoma fosters tumor progression and predicts poor prognosis. PLoS One (2011) 1.34

Quantitative reconstruction of leukocyte subsets using DNA methylation. Genome Biol (2014) 1.32

Mechanisms of cellular communication through intercellular protein transfer. J Cell Mol Med (2010) 1.32

Up for Mischief? IL-17/Th17 in the tumour microenvironment. Oncogene (2010) 1.32

Tumor infiltrating T lymphocytes in colorectal cancer: Tumor-selective activation and cytotoxic activity in situ. Ann Surg (2006) 1.31

Regulatory T cells dampen pulmonary inflammation and lung injury in an animal model of pneumocystis pneumonia. J Immunol (2006) 1.31

Chimeric antigen receptor-engineered T cells for immunotherapy of cancer. J Biomed Biotechnol (2010) 1.30

Detailed analysis of inflammatory cell infiltration in colorectal cancer. Br J Cancer (2013) 1.30

High endothelial venules (HEVs) in human melanoma lesions: Major gateways for tumor-infiltrating lymphocytes. Oncoimmunology (2012) 1.28

Role of type 1 IFNs in antiglioma immunosurveillance--using mouse studies to guide examination of novel prognostic markers in humans. Clin Cancer Res (2010) 1.28

Role of regulatory T cells during virus infection. Immunol Rev (2013) 1.28

The role of the Akt/mTOR pathway in tobacco carcinogen-induced lung tumorigenesis. Clin Cancer Res (2009) 1.27

Once a Treg, always a Treg? Immunol Rev (2014) 1.27

Clinical opportunities and challenges in targeting tumour dormancy. Nat Rev Clin Oncol (2012) 1.26

Monoclonal antibodies for the treatment of cancer. Semin Cancer Biol (2012) 1.26